Ovarian Cancer Clinical Trial
Official title:
HIPEC in Ovarian Cancer: The First Case Control Study in Mexican Patients With 10-year Follow-up
Objectives:
Compare overall survival (OS) and progression‐free survival (PFS) among ovarian cancer
patients who underwent into cytoreduction and HIPEC procedure vs patients who only received
systemic chemotherapy in a 10-years follow up of a case-control study
Methods:
Cases were defined as patients treated by cytoreduction and HIPEC, and were matched (1:2)
with patients treated with chemotherapy only, defined as controls. PFS and OS in the two
groups were measured and compared. PFS was calculated from initiation of treatment to
progression, death or to the last known follow‐up. OS was calculated from initiation of
treatment to death or to the last known follow‐up.
Epithelial ovarian cancer has the highest mortality of all gynecologic tumors in the world
wide. Patients are diagnosed with International Federation of Gynecology and Obstetrics
(FIGO) stage III to IV disease in 75%. The 10-year survival of women with advanced-stage
ovarian cancer is 10% to 15% and has not improve in the past 20 years. Despite treatment with
maximal cytoreductive surgery (CRS) and platinum-based chemotherapy, approximately 70% of
patients with advanced-stage disease relapse within 18 months. Given this high number of
recurrences, new approaches are needed to improve outcomes for these patients. Historically,
peritoneal carcinomatosis represents a devastating form of cancer progression with a very
poor prognosis.
Objectives:
Compare overall survival (OS) and progression‐free survival (PFS) among ovarian cancer
patients who underwent into cytoreduction and HIPEC procedure vs patients who only received
systemic chemotherapy in a 10-years follow up of a case-control study
Methods:
Cases were defined as patients treated by cytoreduction and HIPEC, and were matched (1:2)
with patients treated with chemotherapy only, defined as controls. PFS and OS in the two
groups were measured and compared. PFS was calculated from initiation of treatment to
progression, death or to the last known follow‐up. OS was calculated from initiation of
treatment to death or to the last known follow‐up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |